^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Aranesp (darbepoetin alfa)

    i
    Other names: KRN-321, KRN321
    Associations

    News

    Trials
    Company:
    Amgen, Kyowa Kirin
    Drug class:
    Erythropoiesis stimulating agent
    Related drugs:
    Associations

    News

    Trials
    16d
    DIVI: Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants (clinicaltrials.gov)
    P2, N=120, Recruiting, University of Washington | Trial completion date: Dec 2027 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    Aranesp (darbepoetin alfa)
    3ms
    Darbepoetin Alfa Once Monthly Dosing Schedule Maintains Hemoglobin Concentration Comparable to Every 2 Weeks Dosing Schedule in Advanced Chronic Kidney Disease Patients Not on Dialysis: A Multicenter, Phase 4 Study (clinicaltrials.gov)
    P4, N=40, Active, not recruiting, Gangnam Severance Hospital | N=77 --> 40
    Enrollment change
    |
    Aranesp (darbepoetin alfa)
    4ms
    Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA (clinicaltrials.gov)
    P1/2, N=13, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Oct 2025 --> Jul 2026
    Trial completion date
    |
    Aranesp (darbepoetin alfa) • Ilaris (canakinumab)
    5ms
    DarbeLus: Luspatercept + Darbepoetin in MDS (clinicaltrials.gov)
    P2, N=54, Not yet recruiting, Yale University
    New P2 trial
    |
    Reblozyl (luspatercept-aamt) • Aranesp (darbepoetin alfa)
    6ms
    Darbepoetin Alfa Once Monthly Dosing Schedule Maintains Hemoglobin Concentration Comparable to Every 2 Weeks Dosing Schedule in Advanced Chronic Kidney Disease Patients Not on Dialysis, Multicenter, Phase 4 Study (clinicaltrials.gov)
    P4, N=77, Active, not recruiting, Gangnam Severance Hospital
    New P4 trial
    |
    Aranesp (darbepoetin alfa)
    6ms
    Deucravacitinib Treatment for Psoriasis Complicated by Myelodysplastic Syndrome Without Exacerbation of the Underlying Hematologic Disorder: A Case Report. (PubMed, Cureus)
    Moreover, his anemia remained well controlled without the need for monthly darbepoetin alfa injections. This case highlights the potential of deucravacitinib as a safe and effective treatment option for psoriasis patients with concurrent MDS. Given the emerging understanding of TYK2 as an oncogenic driver in myeloproliferative diseases, further studies are warranted to clarify the therapeutic implications of TYK2 inhibition in this patient population.
    Journal
    |
    TYK2 (Tyrosine Kinase 2)
    |
    Aranesp (darbepoetin alfa)
    7ms
    Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs) (clinicaltrials.gov)
    P3, N=319, Completed, Akebia Therapeutics | Phase classification: P3b --> P3
    Phase classification
    |
    Aranesp (darbepoetin alfa)
    8ms
    Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA (clinicaltrials.gov)
    P1/2, N=13, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Active, not recruiting | N=41 --> 13
    Enrollment closed • Enrollment change
    |
    Aranesp (darbepoetin alfa) • Ilaris (canakinumab)
    9ms
    Protocol for Comparing Hemoglobin Control between Darbepoetin Alfa and Short-acting rHuEPO in Maintenance Hemodialysis Patients (ChiCTR2500096455)
    P4, N=410, Not yet recruiting, Shenzhen Second People's hospital; Shenzhen Second People's hospital
    New P4 trial
    |
    Aranesp (darbepoetin alfa)
    9ms
    Pharmacokinetic/Pharmacodynamic Parameters of NNG-DEPO (Stimus) With Aranesp® (Amgen) in Treatment of Anemia in CKD Patients on Dialysis (clinicaltrials.gov)
    P1, N=43, Completed, Nanogen Pharmaceutical Biotechnology Joint Stock Company | Active, not recruiting --> Completed
    Trial completion
    |
    Aranesp (darbepoetin alfa)
    9ms
    A Study to Compare Efficacy and Safety of Nanogen's Darbepoetin Alfa With Aranesp® (Amgen) in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis (CKD) (clinicaltrials.gov)
    P3, N=214, Completed, Nanogen Pharmaceutical Biotechnology Joint Stock Company | Active, not recruiting --> Completed
    Trial completion
    |
    Aranesp (darbepoetin alfa)
    10ms
    REGIME: Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes (clinicaltrials.gov)
    P3, N=360, Completed, Barts & The London NHS Trust | Unknown status --> Completed
    Trial completion
    |
    Aranesp (darbepoetin alfa) • Neupogen (filgrastim)